NCT05443646View on ClinicalTrials.gov

Consolidation Serplulimab Following Concurrent Chemoradiotherapy for LS-SCLC Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2025

Conditions
Limited Stage Small Cell Lung Cancer
Interventions
DRUG

HLX10

"HLX10 is an innovative monoclonal antibody targeting PD-1，developed by Shanghai Henlius Biotech, Inc.~300mg Q3W"

RADIATION

hypofractionated radiotherapy

45Gy/3Gy/3week

RADIATION

Prophylactic Cranial Irradiation (PCI)

25Gy/2.5Gy/2week

Trial Locations (2)

154007

RECRUITING

Jiamusi Cancer Hospital, Jiamusi

030013

RECRUITING

Shanxi Province Cancer Hospital, Taiyuan

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER